Vestmark Advisory Solutions Inc. Buys Shares of 666 argenex SE $ARGX

Vestmark Advisory Solutions Inc. acquired a new position in shares of argenex SE (NASDAQ:ARGX) in the second quarter, Holdings Channel reports. The firm acquired 666 shares of the company’s stock, valued at approximately $367,000.

Other institutional investors also recently bought and sold shares of the company. WPG Advisers LLC acquired a new position in shares of argenex during the first quarter valued at about $37,000. Brooklyn Investment Group grew its stake in argenex by 102.7% during the 1st quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock valued at $44,000 after purchasing an additional 38 shares during the last quarter. Banque Transatlantique SA acquired a new stake in argenex during the 1st quarter valued at approximately $62,000. Geneos Wealth Management Inc. grew its position in argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after purchasing an additional 99 shares during the period. Finally, Raiffeisen Bank International AG purchased a new stake in shares of argenex in the first quarter worth about $76,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Stock Up 0.4%

NASDAQ ARGX opened at $893.49 on Thursday. The business’s 50-day moving average price is $793.04 and its 200 day moving average price is $668.78. The firm has a market cap of $55.01 billion, a P/E ratio of 38.18, a P/E/G ratio of 0.91 and a beta of 0.45. argenex SE has a 52-week low of $510.05 and a 52-week high of $907.47.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, October 30th. The company reported $4.40 earnings per share for the quarter, beating the consensus estimate of $4.37 by $0.03. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.07 billion. argenex had a return on equity of 29.78% and a net margin of 41.58%. As a group, analysts anticipate that argenex SE will post 3.13 earnings per share for the current year.

Analyst Ratings Changes

ARGX has been the topic of a number of research analyst reports. Evercore ISI lifted their price target on argenex from $775.00 to $910.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Zacks Research lowered shares of argenex from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 21st. Bank of America lifted their price target on shares of argenex from $880.00 to $887.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Piper Sandler increased their price objective on shares of argenex from $820.00 to $930.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Finally, Wall Street Zen upgraded argenex from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, argenex presently has an average rating of “Moderate Buy” and a consensus price target of $879.28.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.